Multidrug-resistant Neisseria gonorrhoeae infection in heterosexual men with reduced susceptibility to ceftriaxone, first report in Thailand.
Adult
Anti-Bacterial Agents
/ pharmacology
Azithromycin
/ pharmacology
Cefixime
/ pharmacology
Ceftriaxone
/ metabolism
Drug Resistance, Bacterial
/ drug effects
Drug Resistance, Multiple
/ genetics
Gonorrhea
/ epidemiology
Heterosexuality
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Molecular Docking Simulation
Neisseria gonorrhoeae
/ genetics
Thailand
/ epidemiology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 11 2021
04 11 2021
Historique:
received:
02
08
2021
accepted:
15
10
2021
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
27
1
2022
Statut:
epublish
Résumé
The global rapid emergence of azithromycin/ceftriaxone resistant Neisseria gonorrhoeae threatens current recommend azithromycin/ceftriaxone dual therapy for gonorrhea to ensure effective treatment. Here, we identified the first two N. gonorrhoeae isolates with decreased ceftriaxone susceptibility in Thailand. Among 134 N. gonorrhoeae isolates collected from Thai Red Cross Anonymous Clinic, Bangkok, two isolates (NG-083 and NG-091) from urethral swab in male heterosexual patients had reduced susceptibility to ceftriaxone (MICs of 0.125 mg/L). Both were multidrug resistant and strong biofilm producers with ceftriaxone tolerance (MBEC > 128 mg/L). NG-083 and NG-091 remained susceptible to azithromycin (MIC of 1 mg/L and 0.5 mg/L, respectively). Reduced susceptibility to ceftriaxone was associated with alterations in PBP2, PBP1, PorB, MtrR, and mtrR promoter region. NG-083 belonged to sequence type (ST) 7235 and NG-091 has new allele number of tbpB with new ST. Molecular docking revealed ceftriaxone weakly occupied the active site of mosaic XXXIV penicillin-binding protein 2 variant in both isolates. Molecular epidemiology results revealed that both isolates display similarities with isolates from UK, USA, and The Netherlands. These first two genetically related gonococcal isolates with decreased ceftriaxone susceptibility heralds the threat of treatment failure in Thailand, and importance of careful surveillance.
Identifiants
pubmed: 34737332
doi: 10.1038/s41598-021-00675-y
pii: 10.1038/s41598-021-00675-y
pmc: PMC8569152
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ceftriaxone
75J73V1629
Azithromycin
83905-01-5
Cefixime
97I1C92E55
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21659Subventions
Organisme : Faculty of Medicine and Graduate School, Chulalongkorn University
ID : Batch No. 39
Organisme : Faculty of Medicine and Graduate School, Chulalongkorn University
ID : Batch No. 39
Organisme : Faculty of Medicine and Graduate School, Chulalongkorn University
ID : Batch No. 39
Organisme : Second Century Fund (C2F) Fellowship
ID : Second Century Fund (C2F) Fellowship
Organisme : Second Century Fund (C2F) Fellowship
ID : Second Century Fund (C2F) Fellowship
Informations de copyright
© 2021. The Author(s).
Références
PLoS Med. 2018 Feb 6;15(2):e1002499
pubmed: 29408881
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Nat Protoc. 2010 Aug;5(8):1460-9
pubmed: 20671729
Sex Transm Dis. 2019 Mar;46(3):e18-e25
pubmed: 30363025
Antimicrob Agents Chemother. 2009 Sep;53(9):4032-4
pubmed: 19546370
PLoS One. 2019 Apr 3;14(4):e0211682
pubmed: 30943191
Sci Rep. 2019 Apr 19;9(1):6300
pubmed: 31004100
J Antimicrob Chemother. 2016 Sep;71(9):2466-70
pubmed: 27178830
J Infect Dis. 2021 Apr 02;:
pubmed: 33822092
Nucleic Acids Res. 2016 Jul 8;44(W1):W236-41
pubmed: 27131786
Sex Health. 2019 Sep;16(5):401-411
pubmed: 31505159
Emerg Infect Dis. 2011 Jan;17(1):148-9
pubmed: 21192886
APMIS. 2007 Aug;115(8):891-9
pubmed: 17696944
Nat Rev Dis Primers. 2019 Nov 21;5(1):79
pubmed: 31754194
Euro Surveill. 2018 Jul;23(27):
pubmed: 29991383
J Biol Chem. 2009 Jan 9;284(2):1202-12
pubmed: 18986991
Euro Surveill. 2011 Oct 27;16(43):
pubmed: 22085601
BMC Infect Dis. 2021 Jun 2;21(1):520
pubmed: 34078300
J Antimicrob Chemother. 2012 Aug;67(8):1858-60
pubmed: 22566592
J Infect Dis. 2006 Aug 1;194(3):307-15
pubmed: 16826478
Sex Transm Infect. 2002 Feb;78(1):72
pubmed: 11872872
Ann Clin Microbiol Antimicrob. 2020 Mar 13;19(1):8
pubmed: 32169075
Clin Infect Dis. 2017 Sep 15;65(6):918-923
pubmed: 28549097
Emerg Infect Dis. 2016 Jun;22(6):1139-41
pubmed: 27191699
MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1911-1916
pubmed: 33332296
Lancet Infect Dis. 2014 Mar;14(3):220-6
pubmed: 24462211
J Vis Exp. 2011 Jan 30;(47):
pubmed: 21307833
Genome Biol. 2014;15(11):524
pubmed: 25410596
Nat Rev Microbiol. 2018 Apr;16(4):226-240
pubmed: 29430011
Syst Biol. 2015 Nov;64(6):1032-47
pubmed: 26227865
BMC Public Health. 2013 Apr 22;13:373
pubmed: 23601556
Emerg Infect Dis. 2018 Feb;24(2):
pubmed: 29131780
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W569-72
pubmed: 22695796
J Antimicrob Chemother. 2020 Nov 1;75(11):3109-3119
pubmed: 32747940
J Acquir Immune Defic Syndr. 2008 Sep 1;49(1):9-16
pubmed: 18667928
J Antimicrob Chemother. 2021 Mar 12;76(4):936-939
pubmed: 33406237
Clin Microbiol Infect. 2006 Aug;12(8):809-12
pubmed: 16842581
N Engl J Med. 2016 Jun 23;374(25):2504-6
pubmed: 27332921
Trends Ecol Evol. 1996 Sep;11(9):367-72
pubmed: 21237881
JAMA. 2021 Feb 9;325(6):523
pubmed: 33560331
Antimicrob Agents Chemother. 2011 Feb;55(2):703-12
pubmed: 21098249
Jpn J Infect Dis. 2017 Mar 24;70(2):213-215
pubmed: 27580580
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80
pubmed: 22155830
BMC Infect Dis. 2020 Nov 5;20(1):809
pubmed: 33153450
Braz J Microbiol. 2017 Oct - Dec;48(4):617-628
pubmed: 28754299
J Infect Dis. 2004 Apr 15;189(8):1497-505
pubmed: 15073688
Nucleic Acids Res. 2015 Feb 18;43(3):e15
pubmed: 25414349
PLoS One. 2019 Aug 9;14(8):e0220990
pubmed: 31398242